**Title**

Guido España1  
1University of Notre Dame,

# Abstract

Abstract content

# Introduction

Text for introduction

# Description of methods

## **subheading**

Text

Table 1. Example of a table

|  |  |  |  |
| --- | --- | --- | --- |
| Description | Fit | Lower 95% CI | Upper 95% CI |
| Average parameter value | 426.69 | 41.02 | 733.75 |

# Results

## **Subheading**

Figure 1. Caption here.

### ***Another subheading***

Some other text

# References

1. van Panhuis WG, Grefenstette J, Jung SY, Chok NS, Cross A, Eng H, et al. Contagious Diseases in the United States from 1888 to the Present. New England Journal of Medicine. 2013;369: 2152–2158. doi:[10.1056/NEJMms1215400](https://doi.org/10.1056/NEJMms1215400)

2. Capeding MR, Tran NH, Hadinegoro SRS, Ismail HIHM, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. The Lancet. 2014;384: 1358–1365.

3. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. [Efficacy of a tetravalent dengue vaccine in children in Latin America. New England Journal of Medicine. 2015;372: 113–123.](https://doi.org/https://doi.org/10.1016/S0140-6736(11)60246-8)